Ongoing Projects
GNR-055
We are working in partnership with Generium to trial GNR-055, a recombinant fusion protein specifically designed for treating mucopolysaccharidosis II (MPS II, Hunter syndrome). Generium is conducting clinical trials in Russia, and Actigen is preparing for clinical trials in other selected markets.
Generium’s Phase 2/3 trials of GNR-055 established proof-of-concept with a favourable side effects profile. GNR-055 crossed the blood-brain barrier and was measured in the cerebrospinal fluid (CSF) where it was proven to be active.
Actigen is committed to the development of GNR-055 in collaboration with our global partners.